• Questions
  • Tournaments
  • Services
  • News
  • Questions
  • Tournaments
  • Questions
  • Questions
Feed Home
👥
Communities
💎
Metaculus Cup
🤖
Q2 AI Benchmarking
🌍
USAID Outlook
🏛️
POTUS Predictions
💵
Fiscal Showdown
Topics
✨🔝
Top Questions
🐦🦠
H5N1 Bird Flu
🕊️🌐
Global Elections
⏳🌀
5 Years After AGI
🇮🇱🇵🇸
Gaza Conflict
🦠🩺
Mpox outbreak
🇺🇦⚔️
Ukraine Conflict
categories
🤖
Artificial Intelligence
🧬
Health & Pandemics
🌎
Environment & Climate
☣️
Nuclear Technology & Risks
See all categories
  • About
  • API
  • FAQ
  • forecasting resources
  • For Journalists
  • Contact
  • Careers
GuidelinesPrivacy PolicyTerms of Use
ForbesScientific AmericanTimeVoxYale NewsNature

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

3%chance

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80%chance

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

62%chance

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%chance

The Promise and Impact of the Next Generation of Weight Loss Drugs

19
1 comment1
Metaculus Journal Archives

Will 10% or more of the top 20 biggest companies in early 2023 still be in the top 20 in 2050?

58%chance